Shijiazhuang Yiling Pharmaceutical (SHE:002603) subsidiary Beijing Yiling has withdrawn its drug registration application for Chaihuang Lidan capsules after receiving approval from China's drug regulator. T
The traditional Chinese medicine is intended to treat chronic cholecystitis and liver-gallbladder damp-heat symptoms, according to a Friday filing with the Shenzhen bourse.
The company said the withdrawal is procedural, noting that the subsidiary will update materials and resubmit the application in line with new regulatory requirements.
Shares of Yiling Pharmaceutical closed 2% lower Friday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments